Screening Strategies in Drug Discovery – Multimedia

We have developed a homogenous bioluminescent assay (GTPase-Glo) system to analyze these proteins in a simple, convenient “add-mix-read” format.

Learn how NanoBRET assays can be used to interrogate protein events such as epigenetic interactions, adaptor recruitment to membrane receptors and proteasomal recruitment of proteins targeted for degradation.

LabTube Meets Catherine Goh, Head of Product Development and Marketing, SiTools Biotech GmbH.

Mark Wigglesworth PhD, Director of High Throughput Screening at AstraZeneca tells us how using cells as models is improving the success of drug discovery.

Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task and is performed only at the later phases of drug development. Therefore the possibility to predict possible sites of human liver microsomal (HLM) metabolism using in silico techniques would be a very attractive feature for any medicinal chemist.

The aim of this study was to establish clonal cell lines stably expressing a channelrhodopsin variant and measure membrane potential changes with a fluorescent dye induced by repetitive light-stimulations in a 96-well plate on a kinetic plate reader FDSS 7000EX.

In this talk, Matthias Nees discusses the development of cell culture model systems to recapitulate key aspects of cancer progression and to functionally validate biomarkers, target genes, and molecular signaling pathways.

Arun Bhunia's research team is currently developing high throughput nano/biosensor-based screening tools such as the fiber optic, cell-based and light scattering for detection of multi-pathogens and toxins from food.

Jonathan Wingfield, principal scientist at AstraZeneca, talks about the AstraZeneca Open Innovation Portal and the use of acoustic mass spectrometry for high-throughput screening.

Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.